Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 4 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Prostatic Neoplasms 118Urinary Bladder Neoplasms 27Carcinoma, Renal Cell 25Kidney Neoplasms 19Neoplasms 14Neoplasm Metastasis 9Breast Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Prostatic Hyperplasia 5Pain 5Lung Neoplasms 5Liver Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Carcinoma, Hepatocellular 4Urologic Neoplasms 3Stomach Neoplasms 3Recurrence 3Prostatic Neoplasms, Castration-Resistant 3Multiple Myeloma 3Kidney Diseases 3Head and Neck Neoplasms 3Carcinoma, Transitional Cell 3Wilms Tumor 2Uterine Cervical Neoplasms 2Tobacco Use Disorder 2Small Cell Lung Carcinoma 2Prostatic Diseases 2Prostate Cancer Metastatic 2Pancreatic Neoplasms 2

Interventions

enzalutamide 1Prednisone 1Gonadotropin-Releasing Hormone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Cognitive Dysfunction × Genitourinary × Clear all
NCT03016741 2026-02-24

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Northwestern University

Phase 4 Active not recruiting
100 enrolled
Genitourinary

Dementia, Prostatic Neoplasms, Cognitive Dysfunction, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡